Gilles Montalescot
A5027244910- Acute Myocardial Infarction Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Coronary Interventions and Diagnostics
- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Cardiac Imaging and Diagnostics
- Lipoproteins and Cardiovascular Health
- Heart Failure Treatment and Management
- Cardiac Valve Diseases and Treatments
- Mechanical Circulatory Support Devices
- Cardiac Structural Anomalies and Repair
- Cardiac Arrhythmias and Treatments
- Cardiac Arrest and Resuscitation
- Cardiovascular Function and Risk Factors
- Cardiovascular and Diving-Related Complications
- Cardiac, Anesthesia and Surgical Outcomes
- Hormonal Regulation and Hypertension
- Diabetes Treatment and Management
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cardiac electrophysiology and arrhythmias
- Health Systems, Economic Evaluations, Quality of Life
- Inflammatory mediators and NSAID effects
- Blood Pressure and Hypertension Studies
- Vascular Procedures and Complications
- Cerebrovascular and Carotid Artery Diseases
Assistance Publique – Hôpitaux de Paris
2016-2025
Fondation pour l’innovation en Cadiométabolisme et Nutrition
2016-2025
Inserm
2016-2025
Sorbonne Université
2016-2025
Pitié-Salpêtrière Hospital
2016-2025
Unité de recherche sur les maladies cardiovasculaires et métaboliques
2015-2024
Hamilton Health Sciences
2017-2024
Universidad Autónoma de Madrid
2024
Radboud University Medical Center
2024
Christ Hospital
2024
Dual-antiplatelet therapy with aspirin and a thienopyridine is cornerstone of treatment to prevent thrombotic complications acute coronary syndromes percutaneous intervention.To compare prasugrel, new thienopyridine, clopidogrel, we randomly assigned 13,608 patients moderate-to-high-risk scheduled intervention receive prasugrel (a 60-mg loading dose 10-mg daily maintenance dose) or clopidogrel 300-mg 75-mg dose), for 6 15 months. The primary efficacy end point was death from cardiovascular...
The ESC Guidelines represent the views of and were arrived at after careful consideration available evidence time they written.Health professionals are encouraged to take them fully into account when exercising their clinical judgement.The do not, however, override individual responsibility health make appropriate decisions in circumstances patients, consultation with that patient where necessary patient's guardian or carer.It is also professional's verify rules regulations applicable drugs...
Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events.
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical...
A substantial proportion of patients receiving fibrinolytic therapy for myocardial infarction with ST-segment elevation have inadequate reperfusion or reocclusion the infarct-related artery, leading to an increased risk complications and death.We enrolled 3491 patients, 18 75 years age, who presented within 12 hours after onset ST-elevation randomly assigned them receive clopidogrel (300-mg loading dose, followed by mg once daily) placebo. Patients received a agent, aspirin, when...
When administered in conjunction with primary coronary stenting for the treatment of acute myocardial infarction, a platelet glycoprotein IIb/IIIa inhibitor may provide additional clinical benefit, but data on this combination therapy are limited.
In patients who have acute myocardial infarction with cardiogenic shock, early revascularization of the culprit artery by means percutaneous coronary intervention (PCI) improves outcomes. However, majority shock multivessel disease, and whether PCI should be performed immediately for stenoses in nonculprit arteries is controversial.In this multicenter trial, we randomly assigned 706 had infarction, to one two initial strategies: either lesion only, option staged lesions, or immediate PCI....
Background— The increasing use of higher-than-approved doses clopidogrel in clinical practice is based part on the desire for greater levels inhibition platelet aggregation (IPA). Prasugrel a new thienopyridine that more potent than standard-dose healthy subjects and patients with stable coronary artery disease. relative antiplatelet effects prasugrel versus high-dose percutaneous intervention are unknown. Methods Results— Comparison to Clopidogrel Inhibition Platelet Activation...
Patients' responses to oral antiplatelet therapy are subject variation. Bedside monitoring offers the opportunity improve outcomes after coronary stenting by individualizing therapy.
Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation.In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes without ST-segment elevation. The primary end point was composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia rehospitalization, or urgent revascularization.Follow-up the trial terminated...
LATELET ACTIVATION PLAYS A critical role both in spontaneous coronary artery thrombosis due to atherosclerotic plaque rupture and thrombotic complications following percutaneous intervention (PCI) with stenting.3][4] However, the optimal tim-
We hypothesized that percutaneous coronary intervention (PCI) preceded by early treatment with abciximab plus half-dose reteplase (combination-facilitated PCI) or alone (abciximab-facilitated would improve outcomes in patients acute ST-segment elevation myocardial infarction, as compared administered immediately before the procedure (primary PCI).In this international, double-blind, placebo-controlled study, we randomly assigned infarction who presented 6 hours less after onset of symptoms...
The cholesteryl ester transfer protein inhibitor evacetrapib substantially raises the high-density lipoprotein (HDL) cholesterol level, reduces low-density (LDL) and enhances cellular efflux capacity. We sought to determine effect of on major adverse cardiovascular outcomes in patients with high-risk vascular disease.
Intravenous cangrelor, a rapid-acting, reversible adenosine diphosphate (ADP) receptor antagonist, might reduce ischemic events during percutaneous coronary intervention (PCI).In this double-blind, placebo-controlled study, we randomly assigned 5362 patients who had not been treated with clopidogrel to receive either cangrelor or placebo at the time of PCI, followed by 600 mg clopidogrel. The primary end point was composite death, myocardial infarction, ischemia-driven revascularization 48...
Although P2Y12 antagonists are effective in patients with non-ST-segment elevation (NSTE) acute coronary syndromes, the effect of timing administration--before or after angiography--is not known. We evaluated administering antagonist prasugrel at time diagnosis versus it angiography if percutaneous intervention (PCI) was indicated.We enrolled 4033 NSTE syndromes and a positive troponin level who were scheduled to undergo within 2 48 hours randomization. Patients randomly assigned receive (a...